220394-93-4

Upstream product

• 67-56-1 methanol 
• 220394-91-2 benzyl 4-isocyanatotetrahydro-1(2H)-pyridinecarboxylate 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 

Downstream Products

• 313501-80-3 1-benzyloxycarbonyl-4-(N-(methoxycarbonyl)-N-(ethyl)amino)piperidine 
• 139062-90-1 piperidin-4-ylmethyl-carbamic acid methyl ester 
• 313501-77-8 4-(N-Methoxycarbonyl-N-(ethyl)amino)piperidine 
• 220394-94-5 4-(methoxycarbonyl-methyl-amino)-piperidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

NEW AZABENZIMIDAZOLE DERIVATIVES

The present invention relates to compounds of general formula I, wherein the group R1, R2, X, Y and z are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

AZABENZIMIDAZOLE DERIVATIVES

The present invention relates to compounds of general formula (I), wherein the group R1, R2, X, Y and z are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes

(2S)-2-(3-Chlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro (2,3-dihydrobenzthiophene-3,4′-piperidin-1′-yl)]butane S-oxide (1b) has been identified as a potent CCR5 antagonist having an IC50 = 10 nM. Herein, structure-activity relationship studies of non-spiro piperidines are described, which led to the discovery of 4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidine derivatives (3-5) as potent CCR5 antagonists.

CYCLIC AMINE MODULATIONS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to cyclic amines of the formula I: STR1 (wherein R 1, R 2, R 3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.